share_log

Belite Bio Presented Interim Results Of LBS-008 Phase 1b/2 Study In Adolescent STGD1 At ARVO Annual Meeting 2022

Belite Bio Presented Interim Results Of LBS-008 Phase 1b/2 Study In Adolescent STGD1 At ARVO Annual Meeting 2022

贝利特生物公司在2022年ARVO年会上公布了青少年STGD1中LBS-008阶段1b/2研究的中期结果
Benzinga Real-time News ·  2022/05/05 08:18
  • LBS-008 (aka Tinlarebant) showed an acceptable safety profile in adolescent Stargardt disease (STGD1) subjects
  • A trend for stabilized or improved visual acuity was observed
  • Observed adverse events were anticipated based on the mechanism of LBS-008 action
  • STGD1 subjects from the Phase 1b study are now participating in the 2-year, Phase 2 extension
  • LBS-008(又名替拉贝坦)在青少年Stargardt病(STGD1)受试者中显示出可接受的安全性
  • 观察到视力稳定或提高的趋势
  • 根据LBS-008的作用机制预测观察到的不良事件
  • 来自1b期研究的STGD1受试者现在正在参与为期2年的2期延期
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发